PDCD1 and diffuse large B-cell lymphoma: Like in mouse DLBCL models, these results suggest that, as long as they are expressed, PD-1 and/or PD-L1 blockade in indolent B-cell lymphomas may synergize with other therapeutic molecules, for example, the specific inhibitors of JAK/STAT pathway, ruxolitinib, or, of BTK, ibrutinib.